Medtronic receives CE Mark for Sentrino CGM system

MINNEAPOLIS – Medtronic, Inc. has announced CE Mark approval of its Sentrino? Continuous Glucose Management System. It is the first minimally invasive continuous glucose monitoring (CGM) system designed specifically for critical care.

The Sentrino CGM system provides an early warning system via real-time trend data, which allows appropriate intervention to prevent glycemic excursions and maximize patient’s time in the target range. The system also integrates simply into the clinical workflow in the hospital, improving quality and efficiency of glucose control maintenance.

“Despite its many benefits, good glycaemic control is difficult to achieve in the CCU, and that’s why we developed Sentrino.  Medtronic has a decade of CGM expertise, and we coupled it with extensive clinical research to develop the Sentrino CGM System for critically ill patients,” said Greg Meehan, vice president and general manager of the Continuous Glucose Monitoring business at Medtronic. “Given the market need for CGM in CCU patients, we believe the market potential will exceed $1 billion globally.”  

The Sentrino CGM system is currently an investigational device in the US and not approved for sale in the US.